Stay updated with breaking news from Mark Bazett. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company at the forefront of developing innovative metallotherapeutics, has announced that...
/PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company developing novel metallotherapeutics, is announcing its selection by Life...
/PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that will be presenting research supporting the use of BOLD-100 in...
Queen's University Belfast, Northern Ireland Van Schaeybroeck's AACR poster presentation "Targeting the DNA repair pathway with BOLD-100 in BRAF-mutant colorectal cancer" (Poster# 1183, Session PO.ET04.03 on April 10) highlights the promising research conducted by the Drug Resistance Group at the Patrick G. Johnston Centre for Cancer Research at Queen's University Belfast, which investigated BOLD-100's mechanism-of-action and identified promising treatment combinations in difficult-to-treat BRAF-mutant colorectal cancers. Colon cancer is one of the most frequently diagnosed malignancies in ad...
COVID-19 cases continue to escalate worldwide The original announcement by the National Research Council of Canada is available at bit.ly/2JRa4fQ. BOLD-100 is a first-in-class ruthenium-based small molecule drug which selectively inhibits stress-induced upregulation of the chaperone protein GRP78. Currently, the investigational treatment is in a Phase 1b clinical trial in gastrointestinal cancer. In cancer, GRP78 plays a critical role in resistance, survival and proliferation, whereas in viral infections, GRP78 plays a critical role in host recognition, viral entry and viral replication. Prec...